# Conotoxins and Prialt

**Type:** work
**Status:** Draft
**Confidence:** High
**Focus:** drug discovery, molecular neuroscience, venom peptides, non-opioid pain, ion channels
**Era:** late 1970s-present; founding peptide discovered 1979, Prialt approved December 2004
**Location:** University of Utah, Salt Lake City, UT
**Updated:** 2026-06-19
**Pull:** *A Utah lab read cone-snail venom as an evolved chemical library and pulled a first-in-class painkiller out of it.*
**Relates:** cites [University of Utah News — New Painkiller Was Born in Utah](conotoxins-utah-news-release.md)
**Relates:** cites [DailyMed — PRIALT (ziconotide) Prescribing Information](conotoxins-dailymed-prialt.md)

## Summary

Baldomero "Toto" Olivera's University of Utah lab spent decades turning the venom of predatory cone snails into a precision toolkit for studying the nervous system. Cone snails immobilize prey with cocktails of small peptides, and Olivera's group showed that many of those peptides — conotoxins — bind specific ion channels and receptors with unusual selectivity.

One peptide, omega-conotoxin MVIIA from the fish-hunting snail *Conus magus*, became the basis for the drug ziconotide, sold as Prialt. The natural peptide was discovered at the University of Utah in 1979 by J. Michael McIntosh, who started in Olivera's lab the summer before his freshman year; he isolated it and determined its structure, and U biologist Doju Yoshikami helped show it blocked transmission between nerve cells. The FDA approved Prialt on December 28, 2004 for severe chronic pain delivered by intrathecal infusion.

## Impact

Severe-pain treatment has long leaned on opioids, which are effective but carry overdose and dependence risk. Ziconotide opened a non-opioid route by blocking N-type voltage-gated calcium channels that help relay pain signals in the spinal cord. It is a difficult drug to use — it has to be infused into the fluid around the spinal cord through an implanted or external pump, and it can cause serious neurological side effects — but it proved that a venom peptide could become an approved human medicine aimed at a nervous-system target.

The broader conotoxin program mattered beyond one drug. Conotoxins became standard probes for sodium channels, calcium channels, nicotinic acetylcholine receptors, NMDA receptors, and other molecular machinery, giving neuroscientists worldwide a reusable library of reagents and drug leads.

## What Was Created

The hard technical problem was that venom is messy: hundreds of similar-looking small peptides, knotted by disulfide bonds, present in tiny quantities, with powerful biological effects. The Utah lab had to purify individual components, determine their structures, synthesize analogs, identify their molecular targets, and connect a toxin's effect on an animal to a human-relevant mechanism.

The conceptual move was to stop treating venom as a crude poison and start treating it as an evolved combinatorial library — each peptide a key shaped for one molecular lock in the nervous system. The 1982 paper by McIntosh, Cruz, Hunkapiller, Gray, and Olivera describing the *Conus magus* peptide is an early marker of that pipeline working end to end. The output was not a single device but a durable research method and a stream of leads.

## Why It Mattered

Prialt is the clearest single proof point: a first-in-class, non-opioid analgesic whose active molecule was discovered in a Utah university lab. The development path then ran outside Utah — the biotech Neurex advanced ziconotide, Neurex was acquired by Elan, and commercial rights later passed to Jazz Pharmaceuticals (U.S.) and Takeda (Europe). That arc is itself instructive about how a university discovery reaches patients.

Just as important, the program helped legitimize venom-derived peptides as serious drug-discovery starting points, and it gave the field a continuing pipeline of candidates for pain and other neural-signaling disorders.

## Utah Context

This is one of Utah's strongest examples of basic biology with global reach: a long-running University of Utah lab, the in-Utah discovery of the founding peptide, and a toolkit now used in neuroscience labs everywhere. It also shows a distinctive feature of the program — undergraduate and very junior researchers playing visible roles in the discovery pipeline, with McIntosh's story being the headline example. It connects to Utah's wider life-sciences ecosystem and sits alongside [Capecchi Gene Targeting and the Knockout Mouse](capecchi-gene-targeting.md) as evidence that Utah basic research has repeatedly changed medicine indirectly.

## People and Institutions

- **Baldomero M. "Toto" Olivera** — University of Utah biologist who founded and led the conotoxin research program.
- **J. Michael McIntosh** — discovered and characterized the natural Prialt peptide as a young University of Utah researcher; later U faculty in psychiatry and biology.
- **Doju Yoshikami** — University of Utah biologist who helped establish that the peptide blocked synaptic transmission.
- **University of Utah conotoxin researchers and students** — purified, synthesized, and tested many venom peptides over decades.
- **Neurex, Elan, Jazz Pharmaceuticals, Takeda** — companies that developed and commercialized ziconotide after the Utah discovery.

## Lessons for Builders

- Reframing a problem can be the breakthrough: treating venom as an evolved library, not a poison, made it searchable.
- A research program with a reusable method outlasts any single product. The conotoxin toolkit keeps generating leads long after Prialt.
- University discovery and commercial approval are different, multi-decade games. Founders translating lab work should expect the development and regulatory path to be longer and more capital-intensive than the discovery.
- Niche approval still counts. Prialt is hard to administer and narrowly used, but it validated an entire non-opioid mechanism.

## Evidence

- [University of Utah News: New Painkiller Was Born in Utah](https://archive.unews.utah.edu/news_releases/new-painkiller-was-born-in-utah/) — [source record](conotoxins-utah-news-release.md)
- [University of Utah Bioscience: Baldomero Olivera](https://bioscience.utah.edu/faculty/olivera/index.php)
- [University of Utah College of Science: From Toxic Cone Snail Venom to Patented Painkiller](https://science.utah.edu/faculty/faculty-research/from-toxic-cone-snail-venom-to-patented-painkiller/)
- [Elan press release (SEC filing): FDA approval of Prialt, December 28, 2004](https://www.sec.gov/Archives/edgar/data/737572/000095016204001502/elan6k122804ex99-1.txt)
- [DailyMed: PRIALT (ziconotide) prescribing information; Initial U.S. Approval 2004](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1) — [source record](conotoxins-dailymed-prialt.md)
- [FDA Label: Prialt (2004)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021060lbl.pdf) — [source record](conotoxins-prialt-sources.md)
- [PMC: Pain Therapeutics from Cone Snail Venoms](https://pmc.ncbi.nlm.nih.gov/articles/PMC6214764/)

## Open Questions

- Consider a source page for the University of Utah "New Painkiller Was Born in Utah" announcement if more pages start citing the discovery chronology.
- Consider a future `people/baldomero-olivera.md` if the wiki begins adding researcher biographies; McIntosh would warrant a cross-link.
- Confirm the current commercial rights-holder for ziconotide before any page makes claims about today's market status.